Investors convinced the executives of Synergen that they needed to evaluate IL-1Ra for a disease with a more rapid outcome. RA studies were too slow to yield a quick profit. Thus, they picked sepsis syndrome.
Data-Driven, Optimal Patient Care and Clinical Research
Expanded opportunities to advance rheumatology will be offered by ACR’s ongoing registry efforts
A Short History of Rheumatoid Arthritis Therapeutics
Or, why I chose to become a rheumatologist
Opening a New Therapeutic Window for Rheumatoid Arthritis
New targets in rheumatoid arthritis: SYK, JAK, BTK
Quality Measurement Improves Rheumatology Outcomes
Innovations in health information technology can have significant impact
Drug Updates: Apremilast, Belimumab, and More
Information on new approvals and medication safety
A&R Abstracts: Methotrexate
For further reading
Old Drugs Can Learn New Tricks
Methotrexate and its mechanism of action
Clinical Trials Go Global
As medical research expands to the global population, will trial results sill apply to U.S. populations?
Drug Updates
Information on new approvals and medication safety
- « Previous Page
- 1
- …
- 113
- 114
- 115
- 116
- 117
- …
- 120
- Next Page »